共 50 条
- [21] A phase II study of ispinesib in patients (PTS) with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSC)ANNALS OF ONCOLOGY, 2006, 17 : 186 - 186Tang, PatriciaSiu, Lillian L.Chen, Eric X.Hotte, Sebastien J.Chia, StephenSchwarz, James K.Colevas, A. DimitriosJohnson, CaitlinPond, Greg R.Winquist, Eric
- [22] A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Bauman, Julie E.Saba, Nabil F.Adkins, DouglasWang, YingHe, YiParadise, ElsaCohen, Roger B.
- [23] Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib StudyCLINICAL CANCER RESEARCH, 2019, 25 (02) : 487 - 495Dillon, Magnus T.Grove, LornaNewbold, Kate L.Shaw, HeatherBrown, Nicholas F.Mendell, JeanneChen, ShuquanBeckman, Robert A.Jennings, AnneRicamara, MarivicGreenberg, JonathanForster, MartinHarrington, Kevin J.
- [24] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II studyANNALS OF ONCOLOGY, 2021, 32 : S806 - S806Shi, Y-K.Gao, L.Tian, Y.Chen, J.Wang, J.Bai, C.Li, X.Su, H.Liu, Z.
- [25] Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysisJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Karamouzis, M. V.Friedland, D.Johnson, R.Rajasenan, K.Branstetter, B.Argiris, A.
- [26] A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1182 - 1183Ronen, O.Shickler, M.Reuveni, H.Israel, I.Haviv, I.Waymack, P. J.Cohen, E.
- [27] Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker AnalysisCLINICAL CANCER RESEARCH, 2022, 28 (08) : 1560 - 1571Kao, Hsiang-FongLiao, Bin-ChiHuang, Yen-LinHuang, Huai-ChengChen, Chun-NanChen, Tseng-ChengHong, Yuan-JingChan, Ching-YiChia, Jean-SanHong, Ruey-Long
- [28] An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Sacco, Assuntina GesualdaChen, RuifengGhosh, DebanjaliWong, Deborah J. L.Worden, Francis P.Adkins, DouglasPittman, EmilyMesser, KarenGold, Kathryn A.Daniels, Gregory A.Swiecicki, PaulSutton, BrianNatsuhara, AmandaCohen, Ezra E. W.
- [29] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyLANCET, 2019, 394 (10212): : 1915 - 1928Burtness, BarbaraHarrington, Kevin J.Greil, RichardSoulieres, DenisTahara, Makotode Castro, Gilberto, Jr.Psyrri, AmandaBaste, NeusNeupane, PrakashBratland, AseFuereder, ThorstenHughes, Brett G. M.Mesia, RicardNgamphaiboon, NuttapongRordorf, TamaraIshak, Wan Zamaniah WanHong, Ruey-LongMendoza, Rene GonzalezRoy, AnanyaZhang, YayanGumuscu, BurakCheng, Jonathan D.Jin, FanRischin, Danny
- [30] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyLANCET, 2019, 393 (10167): : 156 - 167Cohen, Ezra E. W.Soulieres, DenisLe Tourneau, ChristopheDinis, JoseLicitra, LisaAhn, Myung-JuSoria, AinaraMachiels, Jean-PascalMach, NicolasMehra, RaneeBurtness, BarbaraZhang, PingyeCheng, JonathanSwaby, Ramona F.Harrington, Kevin J.